2022

January

• The company has been rated as a “National Green Demonstration Factory” by the Industrial Energy Conservation and Green Development Evaluation Center of the Ministry of Industry and Information Technology.
• The company was awarded the “Tibet Quality Award” by the Selection and Recognition Committee for the First Tibet Quality Award of the Tibet Autonomous Region.
• The subsidiary, Gansu Foge Tibetan Medicine Co., Ltd., has been awarded the title of “Advanced Enterprise Supporting Local Economic and Social Development in 2022.”
• The subsidiary, Gansu Foge Tibetan Medicine Co., Ltd., has been awarded the “Outstanding Investment Promotion Project Award.”

February

• The company was awarded the title of “Advanced Collective in Employment and Entrepreneurship Work of the Tibet Autonomous Region.”
• The subsidiary, Gansu Qizheng Tibetan Medicine Co., Ltd., has been awarded the title of “Workshop for Ethnic Unity and Progress.”

April

• In the 13th China Listed Companies Investor Relations Tianma Awards, the company was awarded the “Best New Media Operations Award for Investor Relations among Chinese Listed Companies,” and Ms. Feng Ping, the company’s Board Secretary, was honored with the “Best Board Secretary Award for Investor Relations among Main Board Listed Companies.”

June

• The company was awarded the A-level tax credit rating by the State Administration of Taxation in Linzhi City for the year 2021.
• The subsidiary, Tibet Tibetan Medicine Group Co., Ltd., was awarded the A-level tax credit enterprise designation by the Lhasa Economic and Technological Development Zone Tax Bureau of the State Administration of Taxation for the year 2021.

July

• The subsidiary, Tibet Tibetan Medicine Group Co., Ltd., has been awarded the “Two-Integration Management System Certification” by the China Classification Society.
• The company ranked 32nd on the “2021 Top 100 Chinese Traditional Chinese Medicine Enterprises” list by the China Association of Traditional Chinese Medicine. The company’s product, Qizheng® Pain Relief Plaster, was included in the “2022 China Pharmaceutical • Brand List.”

August

• The company has been awarded the “2022 Top 500 Chinese Brands” certificate, with a brand value of 8.349 billion yuan.

September

• The company has been recognized as a “Specialized, Fine, and New Small and Medium-sized Enterprise in the Tibet Autonomous Region.”
• Qizheng® Pain Relief Patch and Qizheng® Xigaiwang® Iron Hammer Pain Relief Ointment have been included in the “China Household Essential Medicines List—Top Brands for Topical Pain Relievers” brand ranking; Zhuopanlin® Ten-Flavor Gentian Flower Granules have been included in the “China Household Essential Medicines List—Top Brands for Cough Suppressants and Expectorants” brand ranking.
• The subsidiary, Tibet Tibetan Medicine Group Co., Ltd., has won the second prize in the Tibet region of the 7th “Maker China” SME Innovation and Entrepreneurship Competition for its project “Systematic Re-evaluation and Secondary Development of ‘Ten-Flavor Gentian Capsules’ After Market Launch,” and has also been shortlisted among the top 500 participants in the national competition.
• The company was awarded the Linzhi City Epidemic Contribution Award.

October

• The subsidiary, Tibet Tibetan Medicine Group Co., Ltd., has been designated by the People's Government of Lhasa City as a “Pilot Enterprise for Green Development in Lhasa City.”
• Qizheng® Pain Relief Plaster, Qizheng® Xigaiwang® Iron Hammer Pain Relief Ointment, and Zhuopanlin® Ten-Flavor Gentian Flower Granules have been selected as “2021-2022 China’s Pharmacy Staff’s Most Recommended Brands”;

November

• The subsidiary, Sichuan Zhuopan Linzang Pharmaceutical Technology Co., Ltd., has been awarded the “Two-Integration Management System Certification” by the China Classification Society.
• In the 6th CSR China Education Awards, the company was honored with the “CSR CHINA TOP100 Annual Best Corporate Responsibility Brand” award.
• Qizheng® has been listed on the “2022 Health Industry Brand List” by the China International Fair for Trade in Services (CIFTIS).

December

• The company ranked 31st on the “Top 50 List of China’s Traditional Chinese Medicine R&D Strengths 2022,” unveiled at the 2022 High-Quality Development Conference for the Greater Health Industry and the 7th China Pharmaceutical R&D Innovation Summit (PDI).
• The company has been awarded the “Golden Bee 2022 Outstanding Corporate Social Responsibility Report—Community Responsibility Information Disclosure Award.”
• The subsidiary, Tibet Tibetan Medicine Group Co., Ltd., has won the second prize in the Tibet Science and Technology Innovation Competition for its project “Systematic Re-evaluation and Secondary Development of the ‘Ten-Flavor Gentian Capsules’ After Market Launch.”
• Ms. Feng Ping, the company’s board secretary, has been awarded a 4A rating in the “2022 Evaluation of Board Secretaries’ Performance” by the China Association for Listed Companies.
• The company has been awarded the “Best Practice in Listed Company Annual Report Performance Briefing” prize by the China Association of Listed Companies.
• The company was commended by the Tibet Autonomous Region Ethnic Affairs Commission and recognized as a “Model Collective for Ethnic Unity in Tibet.”
• The company was recognized by the Beijing You Ai You Wei Lai Public Welfare Promotion Center as an “Outstanding Volunteer Service Enterprise.”